Robert J. Ferrante
#160,581
Most Influential Person Now
Robert J. Ferrante's AcademicInfluence.com Rankings
Robert J. Ferrantemedical Degrees
Medical
#3225
World Rank
#3683
Historical Rank
Neurology
#298
World Rank
#380
Historical Rank
Robert J. Ferrantebiology Degrees
Biology
#12694
World Rank
#16188
Historical Rank
Neuroscience
#2148
World Rank
#2209
Historical Rank
Download Badge
Medical Biology
Why Is Robert J. Ferrante Influential?
(Suggest an Edit or Addition)Robert J. Ferrante's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Neuropathological Classification of Huntington's Disease (1985) (2504)
- Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury (1996) (1314)
- Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice (2002) (1096)
- Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine (2000) (1079)
- Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease (2000) (1073)
- A call for transparent reporting to optimize the predictive value of preclinical research (2012) (1036)
- Regional and progressive thinning of the cortical ribbon in Huntington’s disease (2002) (1028)
- Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology (1999) (884)
- Evidence of Increased Oxidative Damage in Both Sporadic and Familial Amyotrophic Lateral Sclerosis (1997) (801)
- Selective sparing of a class of striatal neurons in Huntington's disease. (1985) (785)
- Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis (1999) (689)
- Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice (2003) (687)
- Increased 3‐nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis (1997) (602)
- Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease (2000) (537)
- Oxidative Stress in Huntington's Disease (1999) (500)
- Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. (1995) (480)
- Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease* (2005) (433)
- Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease (1998) (422)
- Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons (1996) (421)
- Therapeutic Effects of Coenzyme Q10 and Remacemide in Transgenic Mouse Models of Huntington's Disease (2002) (408)
- Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease (2003) (404)
- Age‐Dependent Vulnerability of the Striatum to the Mitochondrial Toxin 3‐Nitropropionic Acid (1993) (375)
- Creatine and Cyclocreatine Attenuate MPTP Neurotoxicity (1998) (371)
- Neuronal Nitric Oxide Synthase Activation and Peroxynitrite Formation in Ischemic Stroke Linked to Neural Damage (1999) (369)
- Huntingtin aggregates may not predict neuronal death in Huntington's disease (1999) (352)
- Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox (2003) (343)
- Involvement of Free Radicals in Excitotoxicity In Vivo (1995) (342)
- Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease (2002) (327)
- Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. (2007) (322)
- Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice (2005) (318)
- ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease (2006) (304)
- Morphologic and Histochemical Characteristics of a Spared Subset of Striatal Neurons in Huntington's Disease (1987) (301)
- Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. (2010) (281)
- In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects (2010) (273)
- MPTP induces alpha‐synuclein aggregation in the substantia nigra of baboons (2000) (273)
- Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease (1987) (269)
- Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis (2005) (263)
- Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway (2003) (261)
- Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease (2001) (258)
- Excitotoxin Lesions in Primates as a Model for Huntington's Disease: Histopathologic and Neurochemical Characterization (1993) (254)
- Increased 3‐nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation (1997) (252)
- Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice (2005) (252)
- Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease (1996) (250)
- Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease (2001) (238)
- Sp1 and Sp3 Are Oxidative Stress-Inducible, Antideath Transcription Factors in Cortical Neurons (2003) (235)
- Patterns of cell loss in Huntington's disease (1987) (232)
- Combination therapy with Coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s Diseases (2009) (220)
- Experimental therapeutics in transgenic mouse models of Huntington's disease (2004) (217)
- Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra (1997) (210)
- Differential sparing of somatostatin‐neuropeptide y and cholinergic neurons following striatal excitotoxin lesions (1989) (208)
- Mice lacking alpha-synuclein are resistant to mitochondrial toxins (2006) (197)
- Mitochondrial Cyclic AMP Response Element-binding Protein (CREB) Mediates Mitochondrial Gene Expression and Neuronal Survival* (2005) (192)
- Mechanisms of Reduced Striatal NMDA Excitotoxicity in Type I Nitric Oxide Synthase Knock-Out Mice (1997) (191)
- The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. (2001) (190)
- Chemotherapy for the Brain: The Antitumor Antibiotic Mithramycin Prolongs Survival in a Mouse Model of Huntington's Disease (2004) (185)
- The Cellular and Subcellular Localization of Huntingtin-Associated Protein 1 (HAP1): Comparison with Huntingtin in Rat and Human (1998) (184)
- Inhibition of mitochondrial protein import by mutant huntingtin (2014) (179)
- Nonlinear Decrease over Time in N‐Acetyl Aspartate Levels in the Absence of Neuronal Loss and Increases in Glutamine and Glucose in Transgenic Huntington's Disease Mice (2000) (177)
- The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. (2012) (174)
- 3‐Nitropropionic Acid Neurotoxicity Is Attenuated in Copper/Zinc Superoxide Dismutase Transgenic Mice (1995) (173)
- Heterogeneous Topographic and Cellular Distribution of Huntingtin Expression in the Normal Human Neostriatum (1997) (169)
- Tissue Transglutaminase Is Increased in Huntington's Disease Brain (1999) (164)
- Neuropeptide Y, somatostatin, and reduced nicotinamide adenine dinucleotide phosphate diaphorase in the human striatum: A combined immunocytochemical and enzyme histochemical study (1987) (160)
- Antioxidants modulate mitochondrial PKA and increase CREB binding to D-loop DNA of the mitochondrial genome in neurons. (2005) (152)
- Evidence of Oxidant Damage in Huntington's Disease: Translational Strategies Using Antioxidants (2008) (151)
- Mouse models of Huntington's disease and methodological considerations for therapeutic trials. (2009) (145)
- The Melatonin MT1 Receptor Axis Modulates Mutant Huntingtin-Mediated Toxicity (2011) (142)
- Phase 2 study of sodium phenylbutyrate in ALS (2009) (138)
- Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington disease. (2011) (135)
- Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. (2001) (132)
- Cystamine increases l‐cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation (2004) (132)
- THE GOLGI RAPID METHOD IN CLINICAL NEUROPATHOLOGY: THE MORPHOLOGIC CONSEQUENCES OF SUBOPTIMAL FIXATION (1978) (132)
- Huntington's Disease of the Endocrine Pancreas: Insulin Deficiency and Diabetes Mellitus due to Impaired Insulin Gene Expression (2002) (130)
- Prospective identification of tumorigenic breast cancer cells (2003) (129)
- Depletion of wild‐type huntingtin in mouse models of neurologic diseases (2003) (129)
- Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. (2006) (126)
- Prophylactic Creatine Administration Mediates Neuroprotection in Cerebral Ischemia in Mice (2004) (126)
- Mice Deficient in Group IV Cytosolic Phospholipase A2 Are Resistant to MPTP Neurotoxicity (1998) (126)
- Cytochrome C and caspase-9 expression in Huntington’s disease (2007) (122)
- Modulation of nucleosome dynamics in Huntington's disease. (2007) (120)
- Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum (1986) (117)
- Mice with a Partial Deficiency of Manganese Superoxide Dismutase Show Increased Vulnerability to the Mitochondrial Toxins Malonate, 3-Nitropropionic Acid, and MPTP (2001) (114)
- Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. (2006) (113)
- Sp1 Is Up-regulated in Cellular and Transgenic Models of Huntington Disease, and Its Reduction Is Neuroprotective* (2006) (106)
- Inhibitors of Cytochrome c Release with Therapeutic Potential for Huntington's Disease (2008) (105)
- Neurotoxicity and Oxidative Damage of Beta Amyloid 1–42 versus Beta Amyloid 1–40 in the Mouse Cerebral Cortex (1999) (104)
- Lipoic acid improves survival in transgenic mouse models of Huntington's disease (2001) (102)
- Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis (2013) (100)
- Increased Vulnerability to 3‐Nitropropionic Acid in an Animal Model of Huntington's Disease (1998) (94)
- Malonate produces striatal lesions by indirect NMDA receptor activation (1994) (94)
- Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice (2009) (93)
- MAP Kinase Phosphatase 1 (MKP-1/DUSP1) Is Neuroprotective in Huntington's Disease via Additive Effects of JNK and p38 Inhibition (2013) (92)
- Safety and tolerability of high‐dosage coenzyme Q10 in Huntington's disease and healthy subjects (2010) (87)
- Cdc42-interacting protein 4 binds to huntingtin: Neuropathologic and biological evidence for a role in Huntington's disease (2003) (86)
- Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse (2011) (85)
- Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease (2001) (85)
- Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity. (1999) (82)
- Neuroprotective Effects of Synaptic Modulation in Huntington's Disease R6/2 Mice (2007) (81)
- Studies of hepatic warm ischemia in the obese Zucker rat. (1995) (81)
- Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis (2000) (81)
- Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase (1999) (80)
- Conformation-sensitive Antibodies against Alzheimer Amyloid-β by Immunization with a Thioredoxin-constrained B-cell Epitope Peptide* (2007) (77)
- Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease (2005) (76)
- The therapeutic role of creatine in Huntington's disease. (2005) (75)
- Sequential activation of individual caspases, and of alterations in Bcl‐2 proapoptotic signals in a mouse model of Huntington's disease (2003) (70)
- The cellular pathology of neuronal ceroid-lipofuscinosis. A golgi-electronmicroscopic study. (1977) (69)
- Tyrosine hydroxylase-like immunoreactivity is distributed in the matrix compartment of normal human and Huntington's disease striatum (1987) (68)
- Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3‐nitropropionic acid‐induced striatal damage (2003) (67)
- Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease (2003) (65)
- Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity (2000) (65)
- Oxidative stress is attenuated in mice overexpressing BCL-2 (1999) (65)
- A Human HAP1 Homologue (1998) (61)
- Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease. (2008) (60)
- Role of cyclooxygenase‐2 induction by transcription factor Sp1 and Sp3 in neuronal oxidative and DNA damage response (2006) (59)
- Near‐infrared Fluorescence Spectroscopy Detects Alzheimer's Disease In Vitro (1999) (59)
- Nortriptyline delays disease onset in models of chronic neurodegeneration (2007) (57)
- Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats (2003) (57)
- The neuroprotective role of creatine. (2007) (53)
- Monoallele deletion of CBP leads to pericentromeric heterochromatin condensation through ESET expression and histone H3 (K9) methylation. (2008) (53)
- Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis (2001) (52)
- Topography of nicotinamide adenine dinucleotide phosphate-diaphorase staining neurons in rat striatum (1985) (49)
- Mitochondrial nuclear receptors and transcription factors: Who's minding the cell? (2008) (49)
- Mice Overexpressing 70-kDa Heat Shock Protein Show Increased Resistance to Malonate and 3-Nitropropionic Acid (2002) (47)
- SCAMP5 Links Endoplasmic Reticulum Stress to the Accumulation of Expanded Polyglutamine Protein Aggregates via Endocytosis Inhibition* (2009) (47)
- Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice (2004) (47)
- Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease. (2010) (46)
- Homocysteic acid lesions in rat striatum spare somatostatin—;Neuropeptide Y (NADPH-diaphorase) neurons (1990) (45)
- Iodoacetate Produces Striatal Excitotoxic Lesions (1997) (44)
- Substance P and substance P receptor histochemistry in human neurodegenerative diseases (1992) (44)
- The Wnt Receptor Ryk Reduces Neuronal and Cell Survival Capacity by Repressing FOXO Activity During the Early Phases of Mutant Huntingtin Pathogenicity (2014) (43)
- Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis. (2011) (42)
- Malonate and 3‐Nitropropionic Acid Neurotoxicity Are Reduced in Transgenic Mice Expressing a Caspase‐1 Dominant‐Negative Mutant (2000) (42)
- Huntington's disease: progress and potential in the field (2007) (42)
- Translating therapies for Huntington’s disease from genetic animal models to clinical trials (2004) (41)
- ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis. (2012) (40)
- Activation of Ets‐2 by oxidative stress induces Bcl‐xL expression and accounts for glial survival in amyotrophic lateral sclerosis (2009) (38)
- A novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington disease. (2013) (37)
- Oral dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid (1998) (37)
- 3-Acetylpyridine Produces Age-Dependent Excitotoxic Lesions in Rat Striatum (1994) (37)
- Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis (2011) (36)
- Emerging chemotherapeutic strategies for Huntington’s disease (2005) (31)
- Movement disorder following excitotoxin lesions in primates. (1994) (30)
- Inhibition of white blood cell adhesion at reperfusion decreases tissue damage in postischemic striated muscle. (1996) (27)
- Experimental models of HD and reflection on therapeutic strategies. (2011) (24)
- Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp 1-dependent pathway (2003) (23)
- Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis. (2011) (22)
- Transgenic ALS Mice Show Increased Vulnerability to the Mitochondrial Toxins MPTP and 3-Nitropropionic Acid (2001) (21)
- Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells. (2012) (21)
- Substance P and substance P receptor histochemistry in human neurodegenerative diseases (1992) (19)
- Time course of leukocyte adhesion to endothelium in ischemia-reperfusion. (1996) (19)
- Use of the Silver Nucleolar Organizer Region (AgNOR) Technique in the Differential Diagnosis of Central Nervous System Neoplasia (1992) (17)
- Translational Therapeutic Str ategies in Amyotrophic Lateral Sclerosis (2007) (15)
- The cellular pathology of microgyria (1976) (15)
- A high-throughput screen to identify inhibitors of SOD1 transcription. (2012) (14)
- Chiral cyclohexane 1,3-diones as inhibitors of mutant SOD1-dependent protein aggregation for the treatment of ALS. (2012) (14)
- Uridine ameliorates the pathological phenotype in transgenic G93A-ALS mice (2010) (14)
- Translating therapies for Huntington’s disease from genetic animal models to clinical trials (2004) (13)
- Translational therapeutic strategies in amyotrophic lateral sclerosis. (2007) (12)
- 122 NEUROPATHOLOGIC CLASSIFICATION OF HUNTINGTONʼS DISEASE (1983) (12)
- The isolated human cortex. A Golgi analysis of Krabbe's disease. (1979) (10)
- Mechanisms of Neuronal Degeneration in Huntington’s Disease (1994) (10)
- Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis. (2015) (9)
- Reply from Neil Kowall and colleagues (1987) (8)
- Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice (2006) (7)
- Response:Model of Huntington's disease. (1988) (6)
- Mutant SOD1G93A in bone marrow-derived cells exacerbates 3-nitropropionic acid induced striatal damage in mice (2007) (5)
- NEURONAL AND NEUROPIL LOSS IN THE SUBSTANTIA NIGRA IN HUNTINGTONʼS DISEASE: 239 (1989) (4)
- SUBSTANCE P‐CONTAINING STRIATAL NEURONS IN HUNTINGTON'S DISEASE: 131 (1987) (4)
- THE CELLULAR PATHOLOGY OF CEROID LIPOFUSCINOSIS: A GOLGI-EM STUDY (1976) (3)
- BRIEF COMMUNICATION Mice Overexpressing 70-kDa Heat Shock Protein Show Increased Resistance to Malonate and 3-Nitropropionic Acid (2002) (3)
- Erratum: Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease (Journal of Neurochemistry (2003) 86 (267-272)) (2003) (2)
- 3-Acetoxyandrost-1 , 5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity (2003) (2)
- Histochemical Staining Patterns In Huntington's Disease (1986) (2)
- Huntington ’ s disease : progress and potential in the fi eld (2007) (1)
- P1-011 Neurogenesis is increased in retrosplenial cortex of six month-old Tg2576 mice (2006) (1)
- The pattern of neurodegeneration in the amygdala in dementia with Lewy bodies differs from that found in Alzheimer's disease (2000) (0)
- NEURONAL HEAT SHOCK PROTEIN (HSP 72) IMMUNOREACTIVITY IS INCREASED IN THE STRIATUM AND NEOCORTEX IN HUNTINGTONʼS DISEASE (1993) (0)
- IMMUNOHISTOCHEMICAL LOCALIZATION OF MARKERS FOR OXIDATIVE INJURY IN PARKINSONʼS DISEASE (1997) (0)
- Chapter 3 The Genetic Basis and Molecular Pathogenesis of Huntington's Disease (1999) (0)
- CHAPTER 11 THE NEUROPROTECTIVE ROLE OF CREATINE AUTUMN (2007) (0)
- Response:Physics at the AAAS Annual Meeting 14-19 January 1989 (1988) (0)
- ALPHA-SYNUCLEIN IMMUNOCHEMISTRY ENHANCES DIAGNOSTIC ACCURACY OF NEUROPATHOLOGIC EXAMINATION OF BRAINS FROM PATIENTS WITH DEMENTIA (1999) (0)
- Striatal Organization and Neuronal Degeneration in Huntington's Disease (1988) (0)
- INTRACISTERNAL INFUSION OF SUPEROXIDE DISMUTASE-1 (SOD1) ANTISENSE OLIGODEOXYNUCLEOTIDE CAUSES ANTERIOR HORN CELL DEGENERATION IN VIVO: 24 (1995) (0)
- Identifi cation of compounds protective against G 93 A-SOD 1 toxicity for the treatment of amyotrophic lateral sclerosis (2010) (0)
- Protein Aggregation Inhibitors for ALS Therapy (2013) (0)
- LOCALIZATION OF MULTIPLE HISTOCHEMICAL MARKERS OF OXIDATIVE INJURY IN PROJECTION NEURONS IN ALZHEIMER CORTEX (1996) (0)
- What happens to genes in duplicated genomes (2003) (0)
- Correction to "Chiral Cyclohexane 1,3-Diones as Inhibitors of Mutant SOD1-Dependent Protein Aggregation for the Treatment of ALS". (2017) (0)
- OXIDATIVE INJURY IN THE SPINAL CORDS OF TRANSGENIC MICE EXPRESSING MUTANT HUMAN SUPEROXIDE DISMUTASE (1997) (0)
- ment-binding Protein Activation by AA Adenosine Receptors in Rescuing the Nerve Growth Factor-induced Neurite Outgrowth (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Robert J. Ferrante?
Robert J. Ferrante is affiliated with the following schools:
